Esperion Therapeutics

Esperion Therapeutics, Inc. is a pharmaceutical company. It engages in the development and commercialization of oral therapies for the treatment of patients with elevated low-density lipoprotein cholesterol. The firm offers NEXLETOL (bempedoic acid) tablets, and NEXLIZET (bempedoic acid and ezetimibe) tablets. The company was founded by Roger S. Newton, Hans Ageland, Jan O. Johansson, Anders Paul Wiklund, Michael E. Pape, David I. Scheer and Charles L. Bisgaier in May 1998 and is headquartered in Ann Arbor, MI.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Esperion Therapeutics reports robust Q4 earnings, eyes global expansion

Esperion Therapeutics delivered strong financial results in Q4 2022, driven by successful formulary additions and international partner growth.
The company faces challenges in increasing brand awareness and effectively positioning bempedoic acid post statins, requiring strategic marketing and market access initiatives.
Opportunities lie in leveraging upcoming trial results for label expansion, enhancing brand visibility, and capitalizing on international growth through partnerships.

Esperion Therapeutics excels in Q1 2023, poised for market opportunities

Esperion Therapeutics delivered robust Q1 results with revenue growth and positive market reactions to its studies. While facing legal challenges and operational discussions, the company is well-positioned to leverage opportunities in the market through its strong partnerships and financial stability.

Esperion Therapeutics excels in Q2 earnings, eyes label expansion opportunities

Esperion Therapeutics delivered strong financial performance in Q2 2023, driven by revenue growth, cost management, and strategic partnerships.
While facing challenges in managing expenses, the company is well-positioned to capitalize on market opportunities post-label expansion approvals.
With a solid cash position, ongoing operational efficiency efforts, and a focus on growth initiatives, Esperion is poised for continued success.
The company's commitment to innovation and patient outcomes bodes well for its future growth trajectory and market competitiveness.

Esperion Therapeutics excels in Q3 earnings amidst regulatory hurdles

Esperion Therapeutics delivered strong financial results in Q3 2023, driven by revenue growth and strategic collaborations, despite facing regulatory and litigation challenges.
The company's focus on expanding market presence through FDA approvals and international expansion presents promising growth avenues for future success.
With a solid financial position and ongoing initiatives to drive prescription growth, Esperion is poised to capitalize on market opportunities and navigate challenges effectively.

Esperion Therapeutics reports robust Q4 earnings and eyes market expansion

Esperion Therapeutics delivered strong financial performance in Q4 2023, showcasing significant revenue growth and strategic advancements.
While facing challenges in managing expenses and executing growth strategies, the company is well-positioned to capitalize on market opportunities and drive future expansion.
With a clear roadmap for expense management and a focus on product reach and market expansion, Esperion is poised for continued growth and value creation for stakeholders.
The settlement agreement and label expansion approvals provide a solid foundation for Esperion to leverage opportunities, overcome challenges, and drive sustainable growth.

Esperion Therapeutics posts robust Q1 results amid FDA label wins

Esperion Therapeutics delivered strong financial performance in Q1 2024, driven by revenue growth and FDA label expansions.
The company faces challenges in maintaining prescription growth and navigating payer dynamics post-label update.
Strategic initiatives and market opportunities present avenues for Esperion to capitalize on its recent successes and drive future growth.

Esperion Therapeutics reports robust Q2 revenue growth and global expansion

Esperion Therapeutics delivered strong financial performance in Q2 2024, driven by revenue growth and successful market expansion efforts.
While facing challenges such as debt extinguishment losses and high operating expenses, the company capitalized on opportunities for international growth and product marketability.
By leveraging strengths in expanded product labels and improved market access, Esperion is poised to navigate challenges and capitalize on growth opportunities in the pharmaceutical sector.

Esperion Therapeutics reports robust Q3 performance and eyes global expansion

Esperion Therapeutics delivered strong financial performance in Q3 2024, driven by revenue growth and strategic initiatives to expand market access and product offerings.
While challenges in achieving profitability persist, the company's focus on innovation, global expansion, and operational efficiency underscores its long-term growth potential.
By leveraging strengths in collaboration, research, and market differentiation, Esperion is poised to capitalize on opportunities for further international expansion and brand recognition.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Esperion Therapeutics, Inc. is a pharmaceutical company, which engages in the development and commercialization of oral therapies for elevated low-density lipoprotein cholesterol. The firm offers NEXLETOL (bempedoic acid) tablets, and NEXLIZET (bempedoic acid and ezetimibe) tablets. The company was founded by Roger S. Newton, Hans Ageland, Jan O. Johansson, Anders Paul Wiklund, Michael E. Pape, David I. Scheer and Charles L. Bisgaier in May 1998 and is headquartered in Ann Arbor, MI.

Esperion (ESPR) is set reduce its workforce by 40% and start targeted program savings to reduce its operational expense and deliver consistent growth.

Esperion (ESPR) to Cut 40% Workforce, Revamp Cost Structure

Esperion Therapeutics Inc's (NASDAQ: ESPR) cholesterol drug marketing strategy has soured badly, as it has been struggling to sell its heart disease pill for more than a year. What Happened: The Company says it will cut about 40% of its staff over the next few weeks, or approximately 170 staffers are on the chopping block.

Esperion Chops 40% Workforce As Launch Of Cholesterol Medication Falters

Shares of Esperion Therapeutics Inc. ESPR, -1.72% were down 1.5% in premarket trading on Monday after the company said it plans to reduce its workforce by 40%, citing the challenges of launching two cholesterol-lowering medications during the pandemic. It also said it plans to streamline its commercial strategy, and with those programs in place, Esperion expects to save at least $20 million in 2021.

Esperion Therapeutics to reduce workforce by 40%

– Optimizes organizational structure and operational processes to enable growth as the Company anticipates an inflection post the read-out of the CLEAR Outcomes trial –

ESPERION Announces Plan for Transformative Long-Term Growth

ANN ARBOR, Mich., Sept. 07, 2021 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR), the lipid management company, today announced that it will host an investor webinar on the current landscape and future directions in the treatment of elevated cholesterol on Monday, September 13, 2021 at 1:30pm Eastern Time.

ESPERION to Host Investor Webinar on the Current Landscape and Future Directions in the Treatment of Elevated Cholesterol

Esperion Therapeutics (ESPR) reported earnings 30 days ago. What's next for the stock?

Esperion Therapeutics (ESPR) Down 5.9% Since Last Earnings Report: Can It Rebound?

Esperion's sales following its twin therapy approval have been slow to develop.Esperion's products are entering a crowded marketplace with significant price competition.

Esperion: Hunting Big Game In The Danger Zone

Esperion Therapeutics (ESPR) reports mixed second-quarter results as it beats estimates for earnings but misses the same for sales. Stock down.

Esperion (ESPR) Q2 Loss Narrower Than Expected, Drug Price Up

Esperion Therapeutics, Inc. (ESPR) CEO Sheldon Koenig on Q2 2021 Results - Earnings Call Transcript

Shares of Esperion Therapeutics (NASDAQ:ESPR) remained unaffected after the company reported Q2 results. Quarterly Results Earnings per share were down 138.66% over the past year to ($1.67), which beat the estimate of ($1.84).

Recap: Esperion Therapeutics Q2 Earnings

– U.S. Net Product Revenue of NEXLETOL® (bempedoic acid) Tablets and NEXLIZET® (bempedoic acid and ezetimibe) Tablets Grew 67% Sequentially to $10.6 Million ––  Growth Driven by Increase in Demand and Substantial Improvement in Net Price ––  Prescriptions Grew 28% During the Quarter; More Than 47,800 Patients Have Filled a Prescription for NEXLETOL® (bempedoic acid) Tablets or NEXLIZET® (bempedoic acid and ezetimibe) Tablets ––  Unprecedented CLEAR Outcomes Study Remains On-Track for Complete Major Adverse Cardiac Events (MACE) Accumulation in 2H 2022 –

ESPERION Reports Second Quarter 2021 Financial Results and Provides Company Update

Esperion Therapeutics (ESPR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Earnings Preview: Esperion Therapeutics (ESPR) Q2 Earnings Expected to Decline

ANN ARBOR, Mich., July 13, 2021 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR), today announced it will report second quarter 2021 financial results before the open of the U.S. financial markets on Tuesday, August 3, 2021.

Esperion to Report Second Quarter 2021 Financial Results August 3, 2021

AMC Entertainment

Aterian

GameStop

Gogo

Globalstar

HUYA Inc - ADR

Many investors are taking advantage of short-squeeze stocks by buying heavily shorted stocks when trading at or near all-time lows. The post 7 Names That Could Be The Next Short-Squeeze Stocks appeared first on InvestorPlace.

7 Names That Could Be The Next Short-Squeeze Stocks

Albertsons Companies

Altimeter Growth

Blink Charging

Clover Health Investments

Fulgent Genetics

Arcimoto

Canoo

Nikola

Workhorse Group

Pubmatic

Investors are seeking out the most highly shorted stocks. With GME and AMC seeing monolithic gains, can the same thing be done elsewhere?

12 Most Highly Shorted Stocks Heading Into Q3 2021

Short-sellers who made a bet on Esperion Therapeutics Inc. ( ESPR , Financial) have done well during the past year, but is it time to cash out? While Experion's share price has been cut nearly $30 to about $20 during the past 52 weeks, investment professionals are projecting a reversal of fortune.

Esperion Shorts Have Cleaned Up

– Expansion of management team with proven leader in cardiovascular disease supports advancement of CLEAR Outcomes trial and ESPERION therapeutic pipeline – – Expansion of management team with proven leader in cardiovascular disease supports advancement of CLEAR Outcomes trial and ESPERION therapeutic pipeline –

ESPERION Appoints JoAnne Micale Foody, MD, FACC, FAHA as Chief Medical Officer

Why Is Esperion Therapeutics (ESPR) Up 6.4% Since Last Earnings Report?

Bed Bath & Beyond

DermTech Inc

GEO Group

GTT Communications

IGM Biosciences Inc

Traders often look at short interest to get a sense of how many people are bearish on a stock and how strong the possibility of a short squeeze is. But simply looking at the size of the outstanding short position for a stock might not necessarily be the best indicator of how volatile a stock can be if the shorts begin to cover.

8 Stocks With The Highest Short Interest

ANN ARBOR, Mich., May 24, 2021 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR), today announced that members of Esperion management will participate in two upcoming virtual conferences during the month of June.

Esperion to Participate in Two Upcoming Virtual Investor Conferences

-- Mr. Koenig has 30 years of commercial and operational experience as an accomplished leader in the cardiovascular space;  previously served as ESPERION COO -- -- Succeeds Tim Mayleben, who served as President and CEO for almost a decade and will continue to serve as a senior advisor –

ESPERION Appoints Sheldon Koenig as President and CEO

- Patients with atherosclerotic cardiovascular disease (ASCVD) on maximally tolerated statins and treated with NEXLETOL predicted to experience a 3.3% further absolute reduction in 10-year cardiovascular event risk compared with statins alone (p

Simulation Model based on Pooled Phase 3 Data Demonstrating NEXLETOL® (bempedoic acid) Tablet's Potential to Lower Absolute Cardiovascular Event Risk Presented at ACC.21

Esperion: A Change In Plans After A Disappointing Q1 Earnings

Why Esperion Therapeutics Plummeted Nearly 22% Today

Esperion Therapeutics Inc (NASDAQ: ESPR) reported a first-quarter EPS loss of $3.50, compared to $2.84 a year ago, which missed the analyst consensus estimate of $2.52. The company reported quarterly sales of $7.98 million, which sharply missed the consensus estimate of $26.12 million.

News for Esperion Therapeutics Stock (ESPR)